Small Cell Lung Carcinoma Clinical Trial
Official title:
Phased Avelumab Combined With Chemotherapy as First-line Treatment for Patients With Advanced Small-cell Lung Cancer (SCLC)
PAVE(Phased Avelumab combined with chemotherapy as first-line treatment for patients with advanced small-cell lung cancer) is a Greek, investigator- initiated, single arm open- label phase II study of Avelumab in combination with cisplatin or carboplatin/ etoposide. The study will include an initial safety run-in, open-label, singlearm part (Part 1), and the actual phase II study (Part 2). The total number of patients will not change (the safety run-in patients will be included in the final total number of participants). The safety run-in period will not alter the total study timelines, as phase II accrual will follow immediately after the safety run-in.
Advanced small cell lung cancer (SCLC) remains a disease with dismal prognosis and new therapeutics are urgently needed. SCLC is notably chemosensitive and first-line chemotherapy with platinum analogs and etoposide is associated with high rates of initial objective responses that unfortunately do not last long. The primary endpoint for study design is 1-year PFS rate, where according to RECIST v1.1 PFS is determined as the time from the date of study entry to the date of progression, death from any cause or date of last contact.Secondary End Point is the evaluation of efficacy of the study treatment in terms of Overall Survival (OS), Best Overall Response (BOR), Objective Response Rate (ORR) and Duration of Response (DOR). Evaluation of the safety of the study treatment by assessing Treatment-Emergent Adverse Events (TEAEs). Evaluation of the Quality of Life of patients receiving the study the study treatment. Evaluation of potential biomarkers on fresh or archival sample,of formalin-fixed paraffin embedded tumor tissue block or a minimum of 10 unstained tumor tissue sections. Moreover 10 ml of EDTA-stored blood sample will be collected as well. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05882058 -
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
|
Phase 2 | |
| Terminated |
NCT03963414 -
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04358237 -
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06419179 -
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
|
Phase 2 | |
| Completed |
NCT02874664 -
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02397733 -
Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
|
N/A | |
| Recruiting |
NCT01977235 -
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00759824 -
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
|
Phase 2 | |
| Withdrawn |
NCT02876081 -
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
|
Phase 2 | |
| Recruiting |
NCT06247605 -
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04996771 -
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03662074 -
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
| Completed |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
| Recruiting |
NCT06131840 -
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05683977 -
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
|
||
| Recruiting |
NCT04620837 -
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT05329623 -
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
|
Phase 1 | |
| Active, not recruiting |
NCT04902872 -
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
|
Phase 1/Phase 2 |